Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP
Medical Oncology, 10/06/09

Dincol D et al. – In aggressive non-Hodgkin lymphoma (NHL), CHOP (cyclophosphamide, vincristine, doxorubicin, prednisolone) regimen has been standard for decades, and rituximab has increased response rates and survival in CD20 positive patients, recently. MINE regimen seems to be effective as a consolidation regimen, especially, in intermediate/high risk patients and has low early and late toxicities, an.

Methods

Prospective trial
Aim to evaluate long-term efficacy and toxicity of MINE as consolidation treatment in aggressive NHL patients who achieved CR or unproven CR after 6 cycles of CHOP in first line setting
Primary end-point DFS
38 patients enrolled between February 1992 and May 2000
All of patients received 2 cycles of MINE (mesna 1.3 g/m2, ifosfamide 1.3 g/m2, etoposide 65 mg/m2 on days 1–3, and mitoxantrone 12 mg/m2 on day 1, every 3 weeks) following response to CHOP
Initial bulky disease sites were also applied radiotherapy

Results

Male/female ratio was 1.53
Median age was 49(30–73)
Sixty percent had diffuse large cell histology. Median follow-up time was 118 mos
7 febrile neutropenia episodes
2 patients had grade two neuropathy, 1 had grade three mucositis and another 1 had non-neutropenic pneumonia
No early toxic death
No serious late toxicity observed during long-term follow-up
5- and 10-year DFS rates were both 65.3%. DFS rate in the patients with more than 2 poor prognostic factors according to IPI score is remarkably high (88%)
5- and 10-year OS was 62.5 and 59%, respectively

<< Previous
Cost-effectiveness analysis of trastuzumab (herceptin) in...

Next >>
Pretreatment prognostic factors influencing distant...